AbbVie issues $15B in senior notes across 7 tranches to fund acquisitions and repay debt

AbbVie Inc.

Issued $15.0B aggregate principal of senior notes maturing 2027-2064 with coupons from 4.800% to 5.500%.
Proceeds will prepay $5.0B term loan used for ImmunoGen acquisition and fund pending Cerevel acquisition.
Notes are unsecured, unsubordinated obligations ranking equally with existing unsecured indebtedness.
Underwriters include Morgan Stanley, J.P. Morgan, BofA Securities, and Citigroup.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.